Facing constrained budgets and rising incidence of cancer, Egypt has established a specialist oncology committee and is taking steps towards value-based pricing for drugs. Islam Anan considers the ...

This empirical study demonstrates that a multi-criteria decision analysis (MCDA) framework is a feasible and consistent supplementary tool for evaluating the value of orphan medicinal products (OMPs) ...

The Standing National Committee on Medicines (SNCM) for revision of National List of Essential Medicines felt the need for capacity building for pharmacoeconomics as a discipline in India. The same is ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly approved drugs—and often declared them overpriced—companies in the industry ...

This study analyzed polypharmacy in Côte d'Ivoire using insurance data (2014−2018). It found a high prevalence of multiple medication use, especially among children under 15. While overall rates ...

This series of pharmacoeconomics posts will explore the meaning of $100,000/quality-adjusted life year (QALY) and why it might matter to these 4 P’s: patients, payers, providers, and pharma. Part 1 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. A Leerink Center for Pharmacoeconomics (CPE) Exclusive ...

Pharmacoeconomics is the scientific discipline concerned with the cost and value of drugs, often with the goal of optimizing the allocation of healthcare resources. For example, pharmacoeconomic ...

In the future, most new drugs will need acceptable pharmacoeconomics to qualify for reimbursement. In the U.S., cost of health care is more than 17% of the gross domestic product. Cost containment is ...